G.d. Searle & Company

Monsanto Company

Pharmacia Corporation

General Electric Company

G.d. Searle LLC

Other

Emmyon, Inc.

Chinese Academy of Sciences

Ironwood Pharmaceuticals, Inc.

Microbia, Inc.

Euclises Pharmaceuticals, Inc.

Pharmacia Corporation (of Pfizer, Inc.)

Oxalurx, Inc.

Monsanto Company of St. Louis

Mosanto Company

John Jeffrey Talley

Daniel P Getman

Michael L Vazquez

Gary A DeCrescenzo

Richard A Mueller

John Nicholas Freskos

Matthew James Graneto

Robert M Heintz

Stephen R Bertenshaw

Jeffery S Carter

Donald J Rogier, Jr

Deborah E Bertenshaw

Paul Waddell Collins

Michael John Clare

Thomas Dale Penning

Ish K Khanna

Kathryn L Reed

David Louis Brown

Eric T Sun

Roland S Rogers

Suzanne S Metz

Susan J Hartmann

Ko-Chung Lin

Richard M Weier

James W Malecha

Balekudru Devadas

James A Sikorski

Cathleen Elizabeth Hanau

Srinivasan Raj Nagarajan

Michael A Stealey

Donald J Rogier

Julie M Miyashiro

Xiangdong Xu

Bryan Hurst Norman

Cindy L Ludwig

Francis J Koszyk

Stella S Yu

Yi Yu

Gunnar J Hanson

Daniel L Flynn

Richard A Partis

Michael S South

Shaun Raj Selness

Rajesh Devraj

He Huang

Shashidhar N Rao

Mark G Obukowicz

Lifeng Geng

Shuyuan Liao

Robert Alan Chrusciel

Stephen Hermann Docter

Hwang-Fun Lu

Mark G Currie

Terri L Boehm

David B Reitz

Lijuan Jane Wang

Eduardo J Martinez

William D McGhee

Jinglin J Li

Len F Lee

John Robert Campbell

Daniel Paul Becker

Yan Chen

Deborah A Mischke

Joseph J McDonald

Thomas E Barta

Yvette M Fobian

Clara I Villamil

Monica B Norton

Joseph Gerace Rico

Susan Landis Hockerman

Steven W Kramer

Louis J Bedell

Timothy Claude Barden

G Todd Milne

Brian Cali

James Philip Pearson

Dennis Patrick Riley

Craig N Zimmerman

Barbara B Chen

Barry L Parnas

Johannes Martinus Dina Goossens

Kevin Sprott

James Ross Fishburn

Ara Mermerian

Edward E Yonan

Jeffery N Carroll

Hendrik Verhoogt

Jaime L Masferrer

E Ann Hallinan

Margaret Lanahan Grapperhaus

Mark A Massa

William F Vernier

Bruce C Hamper

Alan Frank Gasiecki

Li Huang Xing

Ashok K Mendiratta

Brent V Mischke

The invention provides ursolic acid morpholine salt. Compositions containing the salt are also provided.

Ursolic acid morpholine salt

The invention provides diethanolamine and morpholine salts of ursolic acid. Compositions containing the salts, and methods of using the salts are also provided.

Ursolic acid morpholine and diethanolamine salts

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

Compounds and methods for treating oxalate-related diseases

Compounds of formula I are disclosed. The compounds are useful for promoting skeletal muscle hypertrophy or treating skeletal muscle atrophy.

Furostan-3-ol derivatives as skeletal muscle hypertrophic agents

Provided herein is a compound of Formula I, or a salt thereof, wherein Ris a moiety having the following structure: wherein Z is selected from the group consisting of O and N; X is selected from the group consisting of a bond, NH, and C(O)NH; and A is selected from the group consisting of substituted aryl and substituted heteroaryl. Compounds of Formula I are useful as opioid receptor agonists. Because the compounds exhibit relatively low levels of &#x3b2;-arrestin recruitment, they do not produce the negative side effects commonly associated with morphine-derived compounds.

Salvinorin derivatives

The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1). 

No-releasing nitrooxy-chromene conjugates

The present invention discloses deuterated benzopyran compounds having structure features as shown in Formula (I), or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof. With excellent anti-inflammatory and analgesic effects and the capability to inhibit growth of tumor cells, such compounds are novel COX-2 selective inhibitors. The compounds and pharmaceutically acceptable salts thereof disclosed by the present application can be applied in preparing anti-inflammatory and analgesic drugs and drugs for treating or preventing tumors. 

Deuterated benzopyran compounds and the use in the treatment of pain and inflammation

Deuterated benzopyran compounds and application thereof

The present disclosure provides phenolic compounds useful in the treatment of neurological conditions such as convulsions and tremors, having the structure of Formula (I): wherein R, R, & R, are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating neurological conditions.

2,5-dialkyl-4-H/halo/ether-phenol compounds

The present disclosure provides NO-releasing guanidine-coxib anti-cancer agents, having the structure of Formula (I): wherein R, R, Z and L are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis, acne, or a disease mediated by arginine deficiency using a compound of Formula (I).

No-releasing guanidine-coxib anti-cancer agents

Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

Indole compounds

The present invention provides NO-releasing NONOate(nitrogen bound)sulfonamide-linked-coxib anti-cancer agents, having the structure of Formula (I): wherein R, X, L, R, R, R, and Z are as defined in the detailed description; pharmaceutical compositions comprising at least one compound of Formula (I); and methods useful for healing wounds, preventing and treating cancer, or treating actinic keratosis, cystic fibrosis or acne, using a compound of Formula (I).

No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: or a pharmaceutically-acceptable salt thereof.A method of treating inflammation or an inflammation-associated disorder in a subject by administering a therapeutically-effective dose of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, or a pharmaceutically-acceptable salt thereof, to the subject.

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder

Growing community of inventors

St. Louis, MO, United States of America

John Jeffrey Talley